clinical research prime

Pediatric Influenza

Pneumococcal: Infants 42-89 Days Old

  • Phase 2 Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31, a 31-Valent pneumococcal conjugate vaccine, to Prevnar 20, when administered concomitantly with routine pediatric vaccinations. 
  • May provide routine pediatric vaccinations are provided at no cost in addition to the study vaccine.
  • Participants will receive study related prevention at no cost and will be compensated for time and travel.

Pneumococcal: Infants 42-89 Days Old

  • Phase 3 study to investigate the safety of a 21-valent pneumococcal conjugate vaccine in healthy infants, compared to Prevnar 20. 
  • Participants will receive study related prevention at no cost and will be compensated for time and travel.
  • **NO BLOOD DRAWS**